Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients with Relapsing-Remitting Multiple Sclerosis.
Therapy Optimization in Multiple Sclerosis: A cohort study of therapy adherence and risk of relapse.
CLIC1 regulates dendritic cell antigen processing and presentation by modulating phagosome acidification and proteolysis.
Clarity Extension Study
MicroRNAs: The Role in Autoimmune Inflammation.
12th International Conference on Myasthenia Gravis and Related Disorders
Brain Cholesterol Metabolism and Its Defects: Linkage to Neurodegenerative Diseases and Synaptic Dysfunction.
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
In Vivo Maintenance of Human Regulatory T Cells during CD25 Blockade.
Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation.
Episode 28 with Dr. Brenda Banwell on pediatric MS
Artesunate Ameliorates Experimental Autoimmune Encephalomyelitis by Inhibiting Leukocyte Migration to the Central Nervous System.
Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.
Influence of infection on exacerbations of multiple sclerosis.
Acorda Therapeutics announces Hatch-Waxman extension of AMPYRA® (dalfampridine) sustained-release formulation patent
Fraction of IL-10+ and IL-17+ CD8 T cells is increased in MS patients in remission and during a relapse, but is not influenced by immune modulators.
[Flow cytometry model for the detection of neutralizing antibodies against of IFN-β].
Myelin Basic Protein Citrullination in Multiple Sclerosis: A Potential Therapeutic Target for the Pathology.
Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus.
Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report.
Glatiramer acetate increases phagocytic activity of human monocytes in vitro and in multiple sclerosis patients.
Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites.
Regulation of dimethyl-fumarate toxicity by proteasome inhibitors.
Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?
Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study.

Pages